Sean D Sullivan
Overview
Explore the profile of Sean D Sullivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
301
Citations
8556
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jofre-Bonet M, McGuire A, Dayer V, Roth J, Sullivan S
Value Health
. 2025 Mar;
PMID: 40049325
Objectives: This study evaluates the impact of biosimilar competition on the price of reference products and biosimilars in the U.S. pharmaceutical market. We focus on Average Sales Price (ASP) dynamics...
2.
Sullivan S, Chaturvedi S, Gautam P, Arnaud A
J Manag Care Spec Pharm
. 2025 Feb;
31(3):277-288.
PMID: 40021467
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug Administration...
3.
Hernandez I, Gabriel N, Pathak Y, Hansen R, Sullivan S
JAMA Health Forum
. 2025 Feb;
6(2):e250012.
PMID: 40019743
No abstract available.
4.
Roth J, Dayer V, Jofre-Bonet M, McGuire A, Sullivan S
BioDrugs
. 2025 Feb;
PMID: 40009310
A biosimilar is a biologic medication that is highly similar to and has no clinically meaningful differences from an existing approved biologic referred to as "reference product." From the introduction...
5.
Cherney D, Drzewiecka A, Folkerts K, Levy P, Millier A, Morris S, et al.
J Med Econ
. 2025 Jan;
28(1):196-206.
PMID: 39783822
Objective: Chronic kidney disease (CKD) is the leading cause of kidney failure, end-stage kidney disease (ESKD), and cardiovascular (CV) events in patients with type 2 diabetes (T2D). The FIDELIO-DKD trial...
6.
Sullivan S, Chaturvedi S, Gautam P, Arnaud A
J Manag Care Spec Pharm
. 2024 Dec;
:1-12.
PMID: 39714307
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug Administration...
7.
Wouters O, Sullivan S, Cousin E, Gabriel N, Papanicolas I, Hernandez I
JAMA
. 2024 Dec;
333(1):85-87.
PMID: 39621331
No abstract available.
8.
Cousin E, Sullivan S, Hansen R, Gabriel N, Kirihennedige A, Hernandez I
J Manag Care Spec Pharm
. 2024 Sep;
30(11):1203-1210.
PMID: 39298335
Background: The Centers for Medicare and Medicaid Services (CMS) recently announced the Maximum Fair Price for the first 10 Medicare Part D drugs selected for price negotiation. By February 2025,...
9.
Chalmers J, Mall M, McShane P, Nielsen K, Shteinberg M, Sullivan S, et al.
Eur Respir Rev
. 2024 Sep;
33(173).
PMID: 39231597
Background: The overall burden of bronchiectasis on patients and healthcare systems has not been comprehensively described. Here, we present the findings of a systematic literature review that assessed the clinical...
10.
Sullivan S, Wouters O, Cousin E, Kirihennedige A, Hernandez I
Value Health
. 2024 Aug;
27(10):1348-1357.
PMID: 39154910
Objectives: By September 2024, the Centers for Medicare and Medicaid Services (CMS) will publicly report the negotiated prices (Maximum Fair Prices) for the first 10 drugs selected for price negotiation....